82 related articles for article (PubMed ID: 9731484)
1. Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I.
Yao S; Murali D; Seetharamulu P; Haridas K; Petluru PN; Reddy DG; Hausheer FH
Cancer Res; 1998 Sep; 58(17):3782-6. PubMed ID: 9731484
[TBL] [Abstract][Full Text] [Related]
2. [Interaction of topotecan-a DNA topoisomerase I inhibitor-with dual-stranded polydeoxyribonucleotides. V. Topotecan is able to cause single- and double-strand breaks in ring superhelical DNA in the absence of enzyme].
Grokhovskiĭ SL; Strel'tsov SA; Zhuze AL
Mol Biol (Mosk); 2003; 37(6):1045-54. PubMed ID: 14714500
[TBL] [Abstract][Full Text] [Related]
3. Interaction of clinically important human DNA topoisomerase I poison, topotecan, with double-stranded DNA.
Streltsov S; Oleinikov V; Ermishov M; Mochalov K; Sukhanova A; Nechipurenko Y; Grokhovsky S; Zhuze A; Pluot M; Nabiev I
Biopolymers; 2003; 72(6):442-54. PubMed ID: 14587067
[TBL] [Abstract][Full Text] [Related]
4. [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. 4. Topotecan binds preferably to the GC base pairs of DNA].
Strel'tsov SA; Mikheĭkin AL; Grokhovskiĭ SL; Oleĭnikov VA; Kudelina IA; Zhuze AL
Mol Biol (Mosk); 2002; 36(5):912-30. PubMed ID: 12391856
[TBL] [Abstract][Full Text] [Related]
5. Action models for the antitumor drug camptothecin: formation of alkali-labile complex with DNA and inhibition of human DNA topoisomerase I.
Streltsov SA
J Biomol Struct Dyn; 2002 Dec; 20(3):447-54. PubMed ID: 12437383
[TBL] [Abstract][Full Text] [Related]
6. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
7. [Interaction of topotecan, DNA topoisomerase I inhibitor, with double-stranded polydeoxyribonucleotides. III. Binding at the minor groove].
Strel'tsov SA; Mikheĭkin AL; Grokhovskiĭ SL; Oleĭnikov VA; Zhuze AL
Mol Biol (Mosk); 2002; 36(3):511-24. PubMed ID: 12068638
[TBL] [Abstract][Full Text] [Related]
8. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
9. Multiple binding modes of the camptothecin family to DNA oligomers.
Bocian W; Kawecki R; Bednarek E; Sitkowski J; Pietrzyk A; Williamson MP; Hansen PE; Kozerski L
Chemistry; 2004 Nov; 10(22):5776-87. PubMed ID: 15472946
[TBL] [Abstract][Full Text] [Related]
10. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
11. Comparative brain tissue distribution of camptothecin and topotecan in the rat.
El-Gizawy SA; Hedaya MA
Cancer Chemother Pharmacol; 1999; 43(5):364-70. PubMed ID: 10100590
[TBL] [Abstract][Full Text] [Related]
12. [Interaction of topotecan--a DNA topoisomerase inhibitor--with dual-stranded polydeoxyribonucleotides. I. Dimerization of topotecan in solution].
Strel'tsov SA; Grokhovskiĭ SL; Kudelina IA; Oleĭnikov VA; Zhuze AL
Mol Biol (Mosk); 2001; 35(3):432-41. PubMed ID: 11443925
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
14. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
[TBL] [Abstract][Full Text] [Related]
15. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
[TBL] [Abstract][Full Text] [Related]
16. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
[TBL] [Abstract][Full Text] [Related]
17. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
19. Reduced albumin binding promotes the stability and activity of topotecan in human blood.
Mi Z; Malak H; Burke TG
Biochemistry; 1995 Oct; 34(42):13722-8. PubMed ID: 7577964
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
